![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of Treatment With Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients With Severe Renal Impairment
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Paul Martin,1 Edward Gane,2 Grisell Ortiz-Lasanta,3 Lin Liu,4 Karim Sajwani,4 Brian Kirby,4 Luisa M. Stamm,4 Diana M. Brainard,4 John G. McHutchison,4 Eric Lawitz,5 Stuart Gordon,6 Richard Robson7
1University of Miami, FL; 2Auckland City Hospital, Auckland, New Zealand; 3Fundación de Investigación, Rio Piedras, PR; 4Gilead Sciences, Inc., Foster City, CA; 5The Texas Liver Institute, UT Health Science Center, San Antonio, TX; 6Henry Ford Health System, Detroit, MI; 7Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand
![AASLD1.gif](../images/120915/120915-10/AASLD1.gif)
![AASLD2.gif](../images/120915/120915-10/AASLD2.gif)
![AASLD3.gif](../images/120915/120915-10/AASLD3.gif)
![AASLD4.gif](../images/120915/120915-10/AASLD4.gif)
![AASLD5.gif](../images/120915/120915-10/AASLD5.gif)
![AASLD6.gif](../images/120915/120915-10/AASLD6.gif)
![AASLD7.gif](../images/120915/120915-10/AASLD7.gif)
![AASLD8.gif](../images/120915/120915-10/AASLD8.gif)
![AASLD9.gif](../images/120915/120915-10/AASLD9.gif)
![AASLD10.gif](../images/120915/120915-10/AASLD10.gif)
![AASLD11.gif](../images/120915/120915-10/AASLD11.gif)
![AASLD12.gif](../images/120915/120915-10/AASLD12.gif)
![AASLD13.gif](../images/120915/120915-10/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|